董事会

Ms. Burzik was appointed to the Board in June 2021. She previously served as President and Chief Executive Officer of Kinetic Concepts, Inc., a global medical device company, from 2006 until the company’s sale in 2011. Prior to this, Ms. Burzik served as President of Applied Biosystems Group and held senior executive positions at Eastman Kodak and Johnson & Johnson, including Chief Executive Officer and President of Kodak Health Imaging Systems and President of Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company. In 2019, Ms. Burzik received the AdvaMed Lifetime Achievement Award that honors accomplishments of pioneers in the medical technology industry whose contributions have had a significant impact on patients’ lives and the industry as an essential part of America’s economy.

目前，Burzik女士是Becton，Dickinson and Company的董事会成员，在那里她担任质量和监管合规委员会主席，并在公司治理和提名委员会以及科学，营销，创新和技术委员会任职。Burzik女士还是Haemonetics Corporation董事会成员，在那里她主席技术委员会，并在审计委员会任职。此外，她还担任STEMBIOSYS，INC。主席双子双子座生物产品公司执行董事长，并担任Xenex Divinfection Services，Inc.。Burzik女士先前曾在达拉斯联邦圣安东尼奥分公司任职储备委员会，Allscripts，Inc。，Bausch＆Lomb，Cordis Corporation和Advamed。

Burris先生于2021年9月被任命为Orthofix董事会和审计委员会。伯里斯（Burris）是全球罗氏诊断财务执行委员会的成员，他被公认为他们的高级领导人之一。

Burris先生除了担任Roche的高级副总裁兼首席财务官外，还担任越来越多的责任感，包括作为糖尿病护理业务的全球金融负责人，他为业务的各个方面提供了财务监督营销，研发，运营，监管和质量。在他的角色中，他在整个罗氏组织中广泛提供了战略和业务发展指导。在加入Roche Diagnostics之前，Burris先生曾是Price Waterhouse LLP的高级经理。

Burris先生是一名经过认证的公共会计师，并拥有巴特勒大学的会计和金融学学士学位。他在扩大和培养印第安纳州生活环境的环境中发挥了作用，同时在许多社区组织中任职，包括成为印第安纳州生物科学研究所的创始委员会成员，以及在生物座无变的董事会和执行委员会中。

汉农先生于2020年6月加入了Orthofix董事会。他是一位经验丰富的医疗设备高管，目前是Mainstay Medical International Plc的总裁兼首席执行官，这是一家总部位于爱尔兰的全球公司，专注于以最低限度的方式转变脊柱手术破坏性，程序整合的解决方案。汉农先生还曾担任Nuvasive，Inc。的总裁兼首席运营官。在Nuvasive的12年期间，他担任了越来越多的责任感，包括国际执行副总裁；和公司发展执行副总裁；和总法律顾问。Hannon先生还担任Sequana Medical NV董事会主任，NV是一家公开交易的医疗设备公司，致力于开发创新治疗方案，以管理肝病，恶性腹水和心力衰竭的流体超负荷。汉农先生拥有斯坦福大学法学院的JD学位，并获得了加州大学伯克利分校的学士学位。

Hinrichs先生于2014年4月被任命为董事会。从2018年到2019年，他担任私人农业生物技术公司Cibus的首席财务官。在此之前，Hinrichs先生曾担任公开交易的诊断公司Alere Inc的执行副总裁兼首席财务官，此前其出售给Abbott Labs。从2010年12月到2015年3月，他在出售给Becton Dickinson之前担任CareFusion Corporation的首席财务官。Hinrichs先生此前曾担任Carefusion高级副总裁，全球客户支持，并担任高级副总裁，负责人。在加入CareFusion之前，他从Cardinal Health，Inc。脱离了Cardinal Health，在Cardinal Health工作，包括执行副总裁和Cardinal Health的公司总裁，并担任其医疗保健供应链服务的执行副总裁兼首席财务官部分。在默克公司（Merck＆Co。）担任了十多年的财务和营销职务后，他加入了红衣主教健康。他拥有卡内基·梅隆大学（Carnegie Mellon University）的本科和研究生学位。Hinrichs先生担任Integer Holdings Corporation，Acutus Medical Inc.和Ottlet Medical的董事。他还担任私人公司Signifier Medical Technologies的总监。

Ms. Marks joined the Board in June 2015. She currently serves as the Vice President for Health Affairs for the University of Colorado and Anschutz Medical Campus, which includes the university’s Schools of Medicine, Dental Medicine, Pharmacy, Public Health, College of Nursing and Graduate School and the University of Colorado Hospital and Children’s Hospital Colorado. Prior to her health campus leadership role, Ms. Marks spent two decades as both Senior Associate Dean for Finance and Administration at the School Of Medicine and Executive Director of University Physicians, Inc., the 501(c)(3) faculty practice plan. She has served as Chair of the Board of Directors of the University of Colorado Hospital and is a board member of the Board of Directors of the Federal Reserve Bank of Kansas City, the Fitzsimons Redevelopment Authority, the Association of Academic Health Centers (AAHC), the Global Down Syndrome Foundation, and the Rose Community Foundation. She was formerly the chair of the board of the Association of American Medical Colleges (AAMC) and is currently a member of the AAMC Advisory Panel on Research and a trustee of the University of Colorado Foundation. Ms. Marks is a graduate of the University of Colorado.

Paolucci先生被任命为董事会成员，并于2016年3月被任命为薪酬委员会。经验丰富的人力资源（HR）高管，他拥有20多年的全球经验直接与董事会和C级高管一起工作提高组织能力和人力资源计划，从而持续改善业务绩效。从2015年到2020年，Paolucci先生在Halozyme之前担任Halozyme Therapeutics Inc.的副总裁兼首席人力资源官，Paolucci先生曾担任执行副总裁兼首席人力资源护理官。Paolucci先生还曾在Nuvasive担任人力资源执行副总裁，并在Life Technologies工作了五年。此前，他曾担任惠普（Hewlett Packard）服务部门的人力资源主管，并在EDS任职几个领导职务，该职位被惠普（Hewlett Packard）收购。在获得HP/EDS之前，Paolucci先生是人力资源咨询公司Perrin的合伙人。Paolucci先生毕业于俄亥俄州立大学。

Mr. Serbousek joined Orthofix in August 2019 and became director, President and CEO in November 2019. A seasoned executive with more than 30 years’ experience in the medical device and biotech industries, Mr. Serbousek served in several leadership positions at Biomet Inc., including Worldwide President of Biomet Biologics, Worldwide Group President of Orthopedics, and President of U.S. Orthopedics. Prior to joining Biomet, he held various general management positions within Medtronic Inc., including Worldwide Division President − Spine, and Worldwide Vice President and General Manager of Biologics for their Spine and Biologics business. Additionally, Mr. Serbousek spent 13 years with DePuy Orthopedics, a Johnson & Johnson company where he served in numerous roles of increasing responsibility, including Vice President of Marketing and Product Development and Vice President of Spinal Operations. Mr. Serbousek has held numerous board positions at for profit and not-for-profit organizations. He earned his BS in Engineering from Washington State University, his MS in Bioengineering from the University of Utah, and later completed several advanced management programs including a program at the IMD International School of Management in Lausanne, Switzerland.

Mr. Sicard joined the Board in March 2018. He currently serves as the President and Chief Executive Officer, and a Board Member of Kinaxis, a global supply chain management software company that delivers cloud-based solutions to some of the world’s largest manufacturing companies, including many in the life science sector. Mr. Sicard joined Kinaxis in 1994 where he has held a number of senior management roles including Chief Product Officer, Chief Strategy Officer, Chief Operating Officer, Executive Vice President of Marketing Development and Service Operations and Vice President of Professional Services. Prior to Kinaxis, Mr. Sicard held positions at FastMAN Software Systems, and Monenco Agra. Mr. Sicard is a graduate of Concordia University, Montreal, Canada, and the Harvard Business School Advanced Management Program.

韦斯特先生被任命为Orthofix董事会成员，并于2021年12月被任命为薪酬和人才发展委员会。毒品设备公司开创了当地的耳朵，鼻子和喉咙外科医生的药物输送选择。作为Intersect Ent的总裁兼首席执行官，他领导了业务从单个技术参与者转变为更全面的ENT公司，导致Medtronic以1.1B美元的价格获得了确定的协议。

在Intersect Ent之前，West先生曾担任Hologic，Inc。诊断解决方案的部门总裁。此外，他在Johnson＆Johnson的职业生涯23年，扮演着各种国内和国际角色，从而增加了各种设备，药品和消费产品的责任。最近，他曾担任糖尿病解决方案公司的全球副总裁，战略和业务发展。他还曾在北美和欧洲，中东和非洲担任J＆J的Lifescan糖尿病公司的部门总裁。

韦斯特先生有A.B.普林斯顿大学的政治和经济学以及宾夕法尼亚大学沃顿商学院的营销和战略管理学院的硕士学位。他是高级医学技术协会（Advamed）董事会成员。